MRK vs DGX
By Alex · Tickerpine
Merck & Co., Inc. vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DGX |
|---|---|---|
| Price | $156.45 | $244.51 |
| Market cap | $385.99B | $26.99B |
| P/E ratio | 120.3 | 26.0 |
| ROE | 6.96% | 14.60% |
| Profit margin | 4.77% | 9.19% |
| Revenue growth | 5.10% | 10.20% |
| Dividend yield | 2.26% | 1.41% |
| Beta | 0.21 | 0.55 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DGX in plain English
- MRK is the bigger company — about 14.3× the market cap of DGX.
- DGX is cheaper on earnings (P/E 26.0 vs 120.3).
- DGX earns a higher return on equity (15% vs 7%).
- DGX is growing revenue faster (10% vs 5%).
- MRK has the higher dividend yield (2.26% vs 1.41%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.